Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

Agenus struck a $141 million agreement with Zydus Lifesciences that it said will accelerate clinical development, scale global manufacturing and expand patient access to its in-development cancer ...

The acquisition will establish Zydus' presence in fast growing global ... stage immuno-oncology company committed to developing immune therapies that effectively combat cancer.

Vitamin C is a powerful antioxidant that plays a crucial role in supporting the immune system, promoting collagen production, and enhancing iron absorption. Since our bodies don’t produce or ...

the vaccine was shown to be safe and to induce potent immune responses in healthy volunteers. Speaking of the partnership, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group, said, ...

The agreement grants Zydus the rights to Agenus' next-generation immunotherapy platform, which is designed to enhance and sustain the immune system's fight against tumor cells. The BOT/BAL ...

In addition, the study will analyse biomarkers such as high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-18, ...